Novartis Faces $3 Billion MS Opportunity and Key Risks

Analyst
โดย Insider Monkey·CH·Read original
Summary · why it matters

Novartis AG could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis if its drug remibrutinib successfully advances through the regulatory process and gains meaningful market share. Bank of America estimates that remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone and potentially more than $10 billion across all indications. The comments follow encouraging results from the REMODEL-1 and REMODEL-2 Phase 3 trials announced on September 2, which showed that remibrutinib reduced relapse activity and met primary endpoints in patients with relapsing multiple sclerosis. The global MS therapeutics market is expected to grow at a 5.9% compound annual growth rate to approximately $38.6 billion by 2030, and Novartis already has a major presence through Kesimpta, which generated approximately $1.42 billion in second-quarter sales, up 32% year over year. However, risks include potential slowdown in Kesimpta growth, competition from Roche's BTK inhibitor, and the uncertainty of regulatory approval and physician adoption. Hedge fund interest is rising, with 38 funds holding stakes in the second quarter, up from 31 in the first quarter, while short interest remains low at approximately 0.26% of public float.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 1 stocks
Novartis AG
NOVN
▲ PositiveTechnologyrelevance

Positive Phase 3 trial results for remibrutinib in MS, with potential $3B peak sales.

Health Care▼ · 1 stocks
Roche Holding AG
ROP
▼ NegativeCompetitionrelevance

Novartis's remibrutinib could compete with Roche's BTK inhibitor in MS.

Financials▲ · 1 stocks
Digital Finance & Tokenization▲ · 1 stocks

Theme Impact 1

Related news

Axsome Therapeutics Reports New Clinical Data in Depression and Alzheimer's Agitation

Axsome Therapeutics reported new clinical data in major depressive disorder and Alzheimer's disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome's central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms, and management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. The company is advancing multiple late-stage clinical programs, including AXS-05, AXS-12, AXS-14, and several solriamfetol indications, and the fresh congress results give more clinical detail around AXS-05 in depression and Alzheimer's agitation, feeding the thesis that future CNS indications can broaden the revenue mix beyond Auvelity, Sunosi and SYMBRAVO. Axsome, a mid-sized US pharmaceuticals player with a market cap of $11.2b, competes alongside larger CNS-focused drug developers such as Biogen and Eli Lilly and smaller specialists. The same update also stress tests a key risk: management must commercialise several CNS assets at once while running high R&D and SG&A spending, with payer scrutiny and strong rivals in both categories.
AXSM ▲
Biotech & Genomic Medicine
Simply Wall St·11hRead more →
▲2

Novartis Acquires Full Rights to Sironax Brain Delivery Platform

Novartis agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier, expanding its toolkit for research into central nervous system disorders where treatment options remain limited. Novartis is a large pharmaceuticals group with a CHF218.8 billion market cap that researches, develops, manufactures, distributes, markets, and sells medicines globally, so gaining access to differentiated delivery technology directly links into its existing focus on complex neurological treatments. The Sironax platform speaks to the same advanced-therapy thesis that underpins Cosentyx's CHMP progress and remibrutinib's Phase 3 data, as Novartis seeks to own hard-to-reach biology where rivals like Roche and Biogen also compete for neurologists' attention. The flip side is that every new modality adds complexity, and recent trial setbacks such as pelacarsen and del-desiran keep development risk front and center, with analysts flagging that stacking capital-intensive projects on top of share buybacks could stretch the balance sheet of a business already carrying a high level of debt.
NOVN.SW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·12hRead more →
2

AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
ABBV ▲
Biotech & Genomic Medicine
Simply Wall St·12hRead more →
© 2026 MarketDXNews